Prothena reports Q2 2026 results, updates year-end cash guidance to $259 million
Roche published Phase 2b PADOVA data on prasinezumab in The Lancet while Prothena trimmed its 2026 cash forecast after share buybacks.
SEC filing
Latest
1 story
Sign inSign in1 story
Roche published Phase 2b PADOVA data on prasinezumab in The Lancet while Prothena trimmed its 2026 cash forecast after share buybacks.
SEC filing